Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* eFFECTOR Therapeutics Inc  EFTR.OQ  reported a quarterly
adjusted loss of 17 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 20 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of 17 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * eFFECTOR Therapeutics Inc shares had fallen by 14.5% this
quarter and gained 66.1% so far this year.
    * The company reported a quarterly loss of $8.36 million.
    * Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:05 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.20          -0.17          Beat
 Mar. 31 2023      -0.14          -0.24          Missed
 Dec. 31 2022      -0.24          -0.22          Beat
 Sep. 30 2022      -0.21          -0.23          Missed

Recent news on Effector Therapeutics

See all news